Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6토실리주맙 이후 초기에 높은 수준의 IL-6은 COVID-19 폐렴에서 생존자와 비생존자를 구별합니다: IL-6의 더 깊은 표적화에 대한 가능한 징후Article Published on 2020-11-012022-09-11 Journal: Journal of medical virology [Category] 바이오마커, 진단, [키워드] 48 hour 48 hours 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected All the patient all the patients baseline blocking cause choice Comparisons coronavirus COVID-19 COVID-19 patients COVID-19 pneumonia cytokine cytokine release storm Cytokine storm discharged dose elevated get out hyperinflammatory state IL-6 interleukin interleukin-6 intravenously Laboratory material nonsurvivor nonsurvivors not different outcomes Patient patients died performed Pneumonia Predictive respiratory serious COVID-19 serum Serum IL-6 Serum level serum levels severe acute respiratory syndrome Coronavirus significantly significantly higher Support survivor tested the cytokine storm Tocilizumab two group two groups [DOI] 10.1002/jmv.26149 PMC 바로가기 [Article Type] Article
Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing MortalityCOVID-19로 입원한 환자의 하이드록시클로로퀸: 사망률을 평가하는 실제 경험Article Published on 2020-11-012022-08-31 Journal: Pharmacotherapy [Category] 신약개발, 임상, [키워드] 30-Day mortality 48 hour 48 hours 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission age all-cause mortality Analysis antimalarial arrhythmia Assessing Azithromycin clinical trial Cohort conditions coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 database diagnosis of COVID-19 experience Follow-up group groups HCQ Hospital admission hospitalized patients Hydroxychloroquine increase in investigated Macrolide male measure medications Mortality no difference Odds ratio off-label on admission outcome overall mortality Patient patients with COVID-19 Primary outcome real-world data receiving respiratory retrospective retrospective cohort study severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 statistically statistically significant the mean were recorded [DOI] 10.1002/phar.2467 PMC 바로가기 [Article Type] Article
Personalising Outcomes after Child Cardiac Arrest (POCCA): design and recruitment challenges of a multicentre, observational studyObservational Study Published on 2020-10-272022-10-05 Journal: BMJ Open [Category] SARS, 임상, [키워드] 48 hour age analysed Analysis arrest Atlanta Biomarker Blood blood sample Brain cardiac Chest Child children clinically cognitive Critical care eligible emotional Enrollment Ethics include inclusion criteria indicated institutional review board Intensive intensive care Intervention investigator IRB magnetic resonance imaging measure Modification Mortality MRI multicentre Multiple neurological neurological injury outcome Paediatric intensive & parent peer-reviewed physical Pittsburgh predict Primary outcome Quality of life receive recruitment Regulatory research coordinator scale secondary survival target Trial university website [DOI] 10.1136/bmjopen-2020-039323 PMC 바로가기 [Article Type] Observational Study
Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical VentilationEmergency Medicine Published on 2020-10-062022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 48 hour acute respiratory syndrome benefit bronchospasm Consensus coronavirus COVID-19 COVID-19 management COVID-19 outbreak Decreased disease IMPROVE intubation Invasive mechanical ventilation Mechanical mortality rate outcome pandemic pathology Patient pharmacological provided regimen survival survival rates Therapeutic approach therapy ventilatory support [DOI] 10.7759/cureus.10822 PMC 바로가기 [Article Type] Emergency Medicine
A Fatal Case of COVID-19 in an Infant with Severe Acute Malnutrition Admitted to a Paediatric Ward in NigerCase Report Published on 2020-09-242022-10-31 Journal: Case Reports in Pediatrics [Category] COVID-19, [키워드] 48 hour Admission Antibiotics chest X-ray Contact COVID-19 COVID-19 outbreak death diarrhoea died difficulty in breathing distress feature Fever Infant Infection intranasal laboratory confirmation less lethargy lung Malnutrition moderate Mortality mother nasal swab Niger oxygen paediatric patients Patient Pneumonia positive potential risk provided reported RT-PCR SARS-CoV-2 severe SARS-CoV-2 Shortness of breath therapeutic ward weight loss while [DOI] 10.1155/2020/8847415 PMC 바로가기 [Article Type] Case Report
COVID-19 diagnosis in a patient with critical limb ischemia: complications and clinical outcomesCase Report Published on 2020-09-212022-10-30 Journal: Jornal Vascular Brasileiro [Category] COVID-19, [키워드] 48 hour Administered angioplastia angioplasty arterial blood flow Chest CT Clinical outcome Complication coughing COVID-19 COVID-19 diagnosis crazy-paving pattern Critical Critical limb ischemia Diabetic diagnosed with COVID-19 died doença arterial obstrutiva periférica Dyspnea endovascular surgery gangrena Gangrene ground glass opacities Hydroxychloroquine intensive care isquemia crítica limb Lungs male necrotic on mechanical ventilation Patient pedal peripheral occlusive arterial disease peroneal artery polymerase chain popliteal positive respiratory symptoms reverse transcription RT-PCR systemic arterial hypertension the patient tratamento endovascular Treatment was performed [DOI] 10.1590/1677-5449.200071 PMC 바로가기 [Article Type] Case Report
Observational study of azithromycin in hospitalized patients with COVID-19코로나19로 입원한 환자를 대상으로 한 아지스로마이신 관찰 연구Research Article Published on 2020-09-032022-08-13 Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, [키워드] 48 hour 48 hours adjusted affected Analysis association Azithromycin azithromycin treatment caused change clinical benefit Cohort cohorts Confusion control patients Cox multivariate model Cox multivariate models Cox regression demonstrated discharge Efficacy Evolution Factors had no hazard ratio hospital Hospital stay hospitalized patient log Lung function multiple therapeutic agent multiple therapeutic agents multivariate Multivariate Cox regression models novel SARS-CoV-2 virus observational study oxygen oxygen saturation Patient patients hospitalized patients treated Primary outcomes Prognostic factors pulmonary disease Result SAFI SAFI ratio SARS-CoV-2 virus small sample size Spain Spread study drug the disease therapeutic agents Treatment with COVID-19 [DOI] 10.1371/journal.pone.0238681 PMC 바로가기 [Article Type] Research Article
Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol지역사회획득 폐렴(RADICAP)에서 항생제 사용을 줄이기 위한 포괄적인 분자 테스트의 영향: 무작위, 통제된, IV상 임상 시험 프로토콜Article Published on 2020-08-202022-09-11 Journal: BMJ Open [Category] MERS, 임상, 진단, [키워드] 1:1 48 hour 48 hours Admission adverse events antibiotic Antibiotic therapy Antibiotic treatment antibiotic use Antibiotics antimicrobial resistance assigned both group both groups causative agent clinical trial ClinicalTrials community-acquired pneumonia De-escalation death Device Diagnosis diagnostic Diagnostic microbiology effective eligible Endpoint Escalation Ethical approval Ethics ethics committee Health health problem hospital hospitalised Hypothesis Immunosuppressed Impact include intensive care intensive care unit admission International intravenous mechanical ventilation Medical devices Medicine molecular molecular diagnostics null hypothesis Open-label parallel group Patient patients Pneumonia primary endpoint Probability protocol randomisation randomised Randomly readmission receive reduce reducing registration number respiratory respiratory infections Result resulting secondary Secondary endpoints Side effects Spanish stability subject [DOI] 10.1136/bmjopen-2020-038957 PMC 바로가기 [Article Type] Article
The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-142022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 48 hour addition Administered adverse effect allergy Alpha anticipated assumed baseline blinded to treatment block clinical Clinical outcome Comorbidity COVID-19 data management Day death determine dissemination drug interaction element eligible eligible participant enrolment evaluate evaluated excluded expected group hospital hospitalised hospitalised patient Hydroxychloroquine independent Intensive intensive care Intervention intervention arms invasive investigator investigator-initiated Laboratory Lopinavir management men New no interaction non-invasive ventilation nucleic acid number objective Open-label outcome participant Patient platform Primary outcome proportion Proportion of participant protocol provided QTC prolongation randomisation randomised randomised controlled trial receive receiving recruited reduce Registered registry representing required researcher Respiratory Support risk Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome sequence significance level Standard of care status stratified study drug Study protocol Tablet total sample size treated Trial two-sided unblinding ventilatory support Virological website women [DOI] 10.1186/s13063-020-04576-9 PMC 바로가기 [Article Type] Letter
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-132022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray [DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter